Spero Therapeutics, Inc. (SPRO) Form 10-Q Quarterly Reports
Spero Therapeutics, Inc. (SPRO) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: SPRO
CIK: 1701108
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2016 12:00:00 AM
Lead Engagement PartnerJohn Coffey
Audit LocationBoston, Massachusetts, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| EFFECT | 2026-09-10 | — | EFFECT Filing | 9999999995-26-002937 | View SEC Doc Filr Page |
| 8-K | 2026-08-28 | 2026-08-28 | 8-K | 0001193125-26-374788 | View SEC Doc Filr Page |
| S-3 | 2026-08-28 | — | S-3 | 0001193125-26-374702 | View SEC Doc Filr Page |
| 8-K | 2026-08-12 | 2026-08-12 | 8-K | 0001193125-26-346855 | View SEC Doc Filr Page |
| 10-Q | 2026-08-12 | 2026-06-30 | 10-Q | 0001193125-26-346795 | View SEC Doc Filr Page |
| 4 | 2026-08-06 | 2026-08-03 | 4 | 0001807743-26-000007 | View SEC Doc Filr Page |
| 3 | 2026-08-06 | 2026-08-03 | 3 | 0001807743-26-000005 | View SEC Doc Filr Page |
| 8-K | 2026-07-14 | 2026-07-08 | 8-K | 0001193125-26-302473 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283245 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283238 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283230 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283226 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283209 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283202 | View SEC Doc Filr Page |
| 4 | 2026-06-25 | 2026-06-23 | 4 | 0001193125-26-283198 | View SEC Doc Filr Page |
| 8-K | 2026-06-25 | 2026-06-23 | 8-K | 0001193125-26-283033 | View SEC Doc Filr Page |
| S-8 | 2026-06-23 | — | S-8 | 0001193125-26-279429 | View SEC Doc Filr Page |
| 8-K | 2026-06-22 | 2026-06-17 | 8-K | 0001193125-26-277506 | View SEC Doc Filr Page |
| 10-Q | 2026-05-13 | 2026-03-31 | 10-Q | 0001193125-26-221591 | View SEC Doc Filr Page |
| 8-K | 2026-05-13 | 2026-05-13 | 8-K | 0001193125-26-221567 | View SEC Doc Filr Page |
| 4 | 2026-05-06 | 2026-05-04 | 4 | 0001193125-26-209884 | View SEC Doc Filr Page |
| ARS | 2026-04-27 | 2025-12-31 | ARS | 0001193125-26-182287 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-27 | — | DEFA14A | 0001193125-26-182256 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-27 | 2026-06-23 | DEF 14A | 0001193125-26-182201 | View SEC Doc Filr Page |
| PRE 14A | 2026-04-13 | 2026-06-23 | PRE 14A | 0001193125-26-153115 | View SEC Doc Filr Page |